Look M, Dunn JP, Kushner RF, et al
While they have not yet been shown to reduce cardiovascular events directly, their use may help support uninterrupted guideline-directed medical therapy (GDMT) and allow clinicians to maintain or up-titrate RAASi and MRA therapy
In the context of weight management, these medications most commonly involve GLP-1 receptor agonists including semaglutide and tirzepatide which work by mimicking gut hormones that regulate appetite, blood sugar, and satiety
In the 2026 clinical landscape, Janumet XR is contraindicated in patients with an eGFR below 30 mL/min/1.73 m2 and generally avoided if eGFR is between 30 and 45 mL/min/1.73 m2
If brain fog persists beyond the first two to three weeks of keto adaptation, look at electrolytes and total caloric intake as the likely causes